Anti-rps6ka1

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

Biochem/physiol Actions

RPS6KA1 (ribosomal protein S6 kinase, 90kDa, polypeptide 1) is also called RSK1 and is activated by mitogenic stimuli via the pathway involving the extracellular signal-regulated kinase (ERK) subfamily of mitogen-activated protein (MAP) kinases. ERK1/ERK2 is activated by MAP kinase kinase (MEK), which is in turn is activated by Raf kinase cascade initiated by GTP-bound form of Ras. The activated ERK1/ERK2 phosphorylates RSK1 and activates it. Activated RSK1 phosphorylates various substrates including transcription factor c-Fos, the cAMP response element binding protein (CREB), the transcriptional inhibitor IκB, the estrogen receptor and the kinase Myt 1, and has been implicated in cell proliferation, differentiation and survival. RSK1 also phosphorylates p27 at T198 and increases RhoA-p27 binding, resulting in inhibition of RhoA and an increase in cell motility.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Features and Benefits

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.Every Prestige Antibody is tested in the following ways: IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. Protein array of 364 human recombinant protein fragments.

General description

RPS6KA1 (ribosomal protein S6 kinase, 90kDa, polypeptide 1) gene encodes a serine/threonine kinase belonging to the RSK (ribosomal S6 kinase) family. The molar mass of this protein is 90kDa and contains two kinase domains. The C-terminal kinase domain functions in autophosphorylation and activation of the amino-terminal kinase domain. The N-terminal kinase domain is involved in phosphotransferase activity.

Immunogen

Ribosomal protein S6 kinase α-1 recombinant protein epitope signature tag (PrEST)

Legal Information

Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC

Linkage

Corresponding Antigen APREST71416.

Physical form

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide